Forward Pharma A/S is a Danish biopharmaceutical company that has been developing a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The company granted Biogen an irrevocable license to all of its intellectual property through a License Agreement and received a non-refundable cash fee of $1.25 billion in February 2017. The company then distributed a return of EUR 917.7 million to shareholders through a capital reduction in September 2017. Forward Pharma A/S may receive royalties from Biogen from their net sales of Tecfidera® or other DMF products for multiple sclerosis outside of the U.S, dependent on a favorable outcome in Europe with respect to the Opposition Proceeding, including any appeal.
Forward Pharma A/S's ticker is FWP
The company's shares trade on the NASDAQ stock exchange
They are based in København K, Denmark
There are 1-10 employees working at Forward Pharma A/S
It is https://forward-pharma.com/
Forward Pharma A/S is in the Healthcare sector
Forward Pharma A/S is in the Biotechnology industry
The following five companies are Forward Pharma A/S's industry peers: